Overview

A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C) in people with abnormal cholesterol levels that may put them at risk for heart disease.

Phase:

Phase 2

Details

Lead Sponsor:

Dr. Reddy's Laboratories Limited

Collaborator:

PharmaNet